Period:
Draw Mode:
| Volume | 10,993 |
|
|||||
| News | - | ||||||
| Day High | 3.99 | Low High |
|||||
| Day Low | 3.71 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Apollomics Inc | APLM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.195 | -4.95% | 3.745 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.98 | 3.71 | 3.99 | 3.745 | 3.94 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 102 | 10,993 | $ 3.85 | $ 42,291 | - | 3.48 - 49.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:10:53 | priorref | 357 | $ 3.745 | USD |
Apollomics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 325.05M | 86.80M | - | 1.45M | -240.81M | -2.77 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Apollomics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APLM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.48 | 4.06 | 3.48 | 3.79 | 7,188 | 0.265 | 7.61% |
| 1 Month | 4.815 | 4.815 | 3.48 | 4.01 | 8,115 | -1.07 | -22.22% |
| 3 Months | 5.35 | 6.20 | 3.48 | 5.13 | 13,148 | -1.61 | -30.0% |
| 6 Months | 18.60 | 49.00 | 3.48 | 9.69 | 101,189 | -14.86 | -79.87% |
| 1 Year | 18.60 | 49.00 | 3.48 | 9.69 | 101,189 | -14.86 | -79.87% |
| 3 Years | 18.60 | 49.00 | 3.48 | 9.69 | 101,189 | -14.86 | -79.87% |
| 5 Years | 18.60 | 49.00 | 3.48 | 9.69 | 101,189 | -14.86 | -79.87% |
Apollomics Description
| Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California. |